Rivastigmine Transdermal Patches Bioequivalence and Adhesion Assessment

Inclusion Criteria: * Body mass index (BMI) between 18.5 and 30.0 kg/m². * Non-smokers or former smokers who stopped smoking at least 1 year prior to screening. * Clinically healthy based on medical history, physical examination, vital signs, ECG, and clinical laboratory tests. * Negative screening for HIV, hepatitis B, and hepatitis C. * Female participants must not be pregnant or breastfeeding and must have a negative pregnancy test. * No hair, wounds, or dermatological conditions at the intended patch application site (upper arm). * Able to understand the study procedures and provide written informed consent Exclusion Criteria: * History or presence of clinically significant cardiovascular, hepatic, renal, gastrointestinal, neurological, psychiatric, metabolic, pulmonary, or dermatological diseases. * Known hypersensitivity to rivastigmine, carbamate derivatives, or any component of the study formulation. * Abnormal clinical laboratory results, vital signs, or ECG considered clinically significant by the investigator. * Positive test results for drugs of abuse, alcohol misuse, HIV, hepatitis B, or hepatitis C. * Use of prescription or non-prescription medications that could interfere with the study drug within a defined period prior to dosing, as determined by the investigator. * Participation in another clinical trial or exposure to an investigational drug within the previous 6 months. * Blood donation or significant blood loss within 3 months prior to the study. * Con…